The overall incidence of #39;adverse events#39; was 14–21 percent in all vaccine-treated groups, says the data published in Lancet. The company says the incidence of adverse events are noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.Bharat Biotech#39;s Covaxin found to be safe, induced immune response in Phase-1
The overall incidence of #39;adverse events#39; was 14–21 percent in all vaccine-treated groups, says the data published in Lancet. The company says the incidence of adverse events are noticeably lower than the rates for other SARS-CoV-2 vaccine platform candidates.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment